GlassScriptPhysician profile
Robert Bruce Perri
NPI 1891179693
$9,633.01
in general payments reported to CMS, 2019-2025
43 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,077 · 2022: $1,802 · 2023: $1,983 · 2024: $1,870 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,754.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,557.22 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,508.49 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,159.24 | 2021-2025 | |
| Amgen INC. | $674.84 | 2021-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $589.67 | 2021-2025 | |
| Lilly USA, LLC | $543.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.64 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $280.05 | 2021-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $273.69 | 2021-2025 | Rexulti |
| Abbott Laboratories | $273.14 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $272.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.44 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Daiichi Sankyo INC. | $231.50 | 2021-2025 | Injectafer |
| Exact Sciences Corporation | $195.12 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $173.98 | 2021-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Perri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.